ArticleBrain tumor pathology2026
Gyriform infiltration indicates tumor invasion burden of isocitrate dehydrogenase 1/2-wildtype gliomas.
Article in Brain tumor pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Few robust radiological markers have been identified for predicting the molecular status of gliomas. Recently, gyriform infiltration (GI) has been identified as an imaging biomarker for molecular glioblastoma (mGBM). This study aimed to validate the diagnostic value of GI in predicting the molecular status of diffuse gliomas. Clinical data were retrospectively collected from patients treated at a single center. Their imaging findings, including GI and the status of molecular markers, including IDH TERT were compared. This study enrolled 137 patients, 16 (12%) of whom, were diagnosed with GI. The vast majority of GI-positive cases were IDH-wildtype (15/16 cases), including four mGBM and six histologically diagnosed glioblastoma cases. The diagnostic sensitivity and specificity of GI in predicting mGBM were 24% and 90%, respectively, and its diagnostic sensitivity and specificity in predicting IDH-wildtype gliomas were 15% and 97%, respectively. GI was also observed in IDH-wildtype gliomas without the molecular and histological features of glioblastoma. All five GI-positive cases with available
Indexed as
Identifiers
41066007What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.